This is our editorial hub for semaglutide. It covers what the drug is, what Wegovy, Ozempic, and Rybelsus cost in 2026, how the FDA-approved dose ladders work, and where the compounded semaglutide market sits after the 2025 regulatory deadlines. Each section below links to the full coverage on its topic. Our editorial voice is neutral. We do not sell semaglutide, take affiliate payments on our pillar or explainer pages, or recommend specific telehealth providers.
Semaglutide at a Glance
- Active ingredient: semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk.
- Branded products: Wegovy (FDA-approved for chronic weight management and cardiovascular risk reduction), Ozempic (FDA-approved for Type 2 diabetes), and Rybelsus (oral tablet, FDA-approved for Type 2 diabetes). Same molecule, three indications.
- Administration: Wegovy and Ozempic are once-weekly subcutaneous injections in the abdomen, thigh, or upper arm. Rybelsus is a once-daily oral tablet.
- Wegovy dose range: 0.25 mg starter, titrating to 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg maintenance. The Wegovy HD 7.2 mg pen is a higher-dose option.
- Monthly cost range (2026): roughly $25 with a savings card on covered commercial insurance, $149 to $399 for cash-pay through NovoCare Pharmacy direct, and $1,027 to $1,349 at retail without insurance.
- Compounded status: direct copies of Wegovy and Ozempic are no longer broadly permitted after the April 22, 2025 (503A) and May 22, 2025 (503B) deadlines. Licensed pharmacies still produce personalized or combination formulations under a narrower regulatory pathway.
What does semaglutide do?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a gut hormone that regulates appetite, satiety, gastric emptying, and the body's insulin response to food. By mimicking GLP-1's action at its receptor, semaglutide reduces appetite, slows stomach emptying, and improves glycemic control. The mechanism is GLP-1-only, which distinguishes it from tirzepatide (Mounjaro, Zepbound), a dual GLP-1 / GIP agonist. For the full head-to-head efficacy comparison, see our semaglutide vs tirzepatide guide.
Semaglutide is FDA-approved under three brand names. Wegovy is approved for chronic weight management in adults and adolescents with obesity (or overweight with at least one weight-related condition) and for reducing the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease. Ozempic is approved for Type 2 diabetes and for cardiovascular risk reduction in adults with Type 2 diabetes and established cardiovascular disease. Rybelsus is the oral tablet form, approved for Type 2 diabetes. The molecule is identical across the three products; the dose ladders, formulations, and FDA-approved indications differ.
Our Full Semaglutide Coverage
Four deep-dive articles cover the main decisions patients and caregivers face in 2026: what semaglutide costs across all three brand names, what compounded semaglutide is after the 2025 regulatory shift, the full side-effect profile from the FDA-approved labels, and how semaglutide compares head-to-head with tirzepatide. Each is linked below with a short summary.
How much does semaglutide cost in 2026?
The monthly cost of semaglutide in 2026 is not a single number. It branches on which brand name, insurance status, and which pharmacy channel you use. Six main paths exist:
- Retail pharmacy without insurance, Wegovy: approximately $1,349 per month at list price.
- Retail pharmacy without insurance, Ozempic: approximately $1,027 per month at list price.
- NovoCare Pharmacy direct (Wegovy cash-pay): $199 per month for 0.25 mg and 0.5 mg pens through June 30, 2026, then $349 per month for standard pens, and $399 per month for the Wegovy HD 7.2 mg pen.
- NovoCare Pharmacy direct (Rybelsus cash-pay): $149 per month for 1.5 mg and 4 mg tablets, with the 4 mg intro price stepping up after August 31, 2026.
- Commercial insurance + manufacturer savings card: as low as $25 per fill for eligible patients on Wegovy or Ozempic, capped at $100 per month in savings.
- Compounded semaglutide: typically $200 to $500 per month where still available, plus telehealth platform fees.
For the full breakdown, including how the NovoCare Pharmacy direct program works, the fine print on savings cards, public-program coverage, and hidden costs, see our complete semaglutide cost guide.
What is the semaglutide dose schedule?
Each brand of semaglutide has its own FDA-approved dose ladder, designed for the indication and tolerability of the patient population.
Wegovy (chronic weight management)
The Wegovy dose ladder for chronic weight management starts at 0.25 mg once weekly for 4 weeks. The dose then steps up at 4-week intervals to 0.5 mg, 1 mg, 1.7 mg, and the 2.4 mg maintenance dose, the target dose for chronic weight management. Reaching 2.4 mg takes a minimum of 16 weeks of weekly injections. The Wegovy HD 7.2 mg pen is a separate higher-dose option for patients with appropriate clinical indication.
Ozempic (Type 2 diabetes)
Ozempic for Type 2 diabetes starts at 0.25 mg once weekly for 4 weeks, then increases to 0.5 mg, 1 mg, and a maximum of 2 mg weekly. The starter 0.25 mg dose is for tolerance only and is not effective for glycemic control on its own.
Rybelsus (oral, Type 2 diabetes)
Rybelsus is taken once daily by mouth on an empty stomach with no more than 4 ounces of water, at least 30 minutes before food, drink, or other oral medications. Standard dosing starts at 3 mg daily for 30 days for tolerance, then 7 mg, with a maintenance option of 14 mg if needed. NovoCare Pharmacy currently lists Rybelsus 1.5 mg and 4 mg as the cash-pay tablet strengths.
Is compounded semaglutide still legal in 2026?
From 2022 through early 2025, semaglutide injection sat on the FDA's drug shortage list. That status triggered an enforcement-discretion window under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which allowed state-licensed and FDA-registered pharmacies to compound copies of semaglutide to meet patient demand. The FDA declared the semaglutide injection shortage resolved on February 21, 2025.
The compounding wind-down dates followed: state-licensed 503A pharmacies had until April 22, 2025 to stop compounding copies of Ozempic and Wegovy, and 503B outsourcing facilities had until May 22, 2025. In April 2026, the FDA further clarified that a compounded product pairing semaglutide with vitamin B12 is treated as essentially a copy of Wegovy or Ozempic when the semaglutide strength is within 10 percent of the commercial equivalents, narrowing the personalized-formulation pathway. A narrow exception remains for compounders filling four or fewer prescriptions of a given compounded product per calendar month.
For the full legal and clinical context, what 503A versus 503B means, how to evaluate a compounding pharmacy, and what patients currently on compounded semaglutide should know, see our compounded semaglutide explainer.
Frequently Asked Questions
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk. The FDA has approved it under three brand names: Wegovy for chronic weight management and cardiovascular risk reduction, Ozempic for Type 2 diabetes, and Rybelsus for oral Type 2 diabetes therapy. The molecule is the same across all three brands.
What's the difference between Wegovy, Ozempic, and Rybelsus?
All three contain semaglutide. Wegovy is approved for chronic weight management and cardiovascular risk reduction. Ozempic is approved for Type 2 diabetes and cardiovascular risk reduction in patients with Type 2 diabetes. Rybelsus is the oral tablet form, approved for Type 2 diabetes. The dose ladders, formulations, and FDA-approved indications differ across the three; the molecule does not.
How much does semaglutide cost per month in 2026?
Brand-name semaglutide lists at $1,349.02 per package for Wegovy and $1,027.51 per fill for Ozempic. NovoCare Pharmacy direct cash-pay runs $199 to $399 per month for Wegovy and $149 per month for Rybelsus. With commercial insurance and a manufacturer savings card, eligible patients can pay as little as $25 per fill. Compounded pricing varies and has shifted since the 2025 FDA deadlines.
What is the correct semaglutide dose for weight loss?
Wegovy is the FDA-approved semaglutide product for chronic weight management. The dose ladder starts at 0.25 mg once weekly for 4 weeks, then steps up to 0.5 mg, 1 mg, 1.7 mg, and the 2.4 mg maintenance dose. The Wegovy HD 7.2 mg pen is a higher-dose option for patients with appropriate clinical indication.
Is compounded semaglutide still available in 2026?
Direct copies of Wegovy and Ozempic from compounding pharmacies are no longer broadly permitted. The 503A enforcement-discretion window ended April 22, 2025, and the 503B window ended May 22, 2025. Licensed 503A and 503B pharmacies still produce personalized or combination semaglutide formulations under a narrower regulatory pathway, but the economics and provider availability changed significantly compared with the 2022 to early 2025 shortage window.
Is there a generic version of semaglutide?
No. Semaglutide is under patent protection held by Novo Nordisk, with key US patents not expected to expire until the early 2030s. Compounded semaglutide is not a generic; it is produced under a separate regulatory pathway for compounded preparations, not through the FDA's abbreviated new drug application process that brings generics to market.
How We Cover Semaglutide
Every article in our semaglutide coverage follows the standards described in our editorial policy. Every specific numerical or factual claim is verified live against a primary source in the drafting session: the FDA-approved label via DailyMed, FDA guidance documents, dated Novo Nordisk pricing pages on wegovy.com and novocare.com, and peer-reviewed trial publications via PubMed. Our coverage is reviewed by a credentialed expert before publication.
We do not take affiliate payments on our pillar or explainer pages, do not recommend specific telehealth providers, and do not accept directed coverage in exchange for editorial content. To report a factual error in any article, email editorial@healthymealsincentives.org; corrections are reviewed within five business days.
Written By
Rachel Nguyen, MS, RDN
Rachel is a registered dietitian with over a decade of experience in nutrition policy and the economics of health. Her current editorial focus covers GLP-1 medications, obesity medicine, and the intersection of nutrition and pharmaceutical treatment. She holds a Master of Science in Nutrition from the University of North Carolina.
Expert Reviewer
Dr. Kevin Park, PhD
Dr. Park is a nutrition education researcher focused on federal nutrition programs and dietary outcomes. His work has been published in the Journal of School Health and the Journal of the Academy of Nutrition and Dietetics. He reviewed this hub's nutrition and public-health content. Clinical decisions about semaglutide therapy should be made with a licensed prescriber.